What are the different types of lymphoma and their respective prognoses?

Types of Lymphoma and Prognosis

Lymphomas are divided into two major categories—Hodgkin lymphoma (HL, 10% of cases) and non-Hodgkin lymphoma (NHL, 90% of cases)—with dramatically different prognoses: HL is now curable in at least 80% of patients, while NHL prognosis varies widely by subtype, ranging from indolent but incurable to aggressive but potentially curable disease. 1, 2

Major Lymphoma Categories

Hodgkin Lymphoma (HL)

HL comprises two main types with distinct characteristics:

Classic Hodgkin Lymphoma (CHL) - 95% of HL cases 1

• Subtypes: Nodular sclerosis CHL, mixed cellularity CHL, lymphocyte-depleted CHL, and lymphocyte-rich CHL
• Prognosis: Excellent—5-year survival rates have improved so markedly that treatment considerations now focus primarily on minimizing long-term toxicity rather than improving cure rates 1
• Cure rate: At least 80% of patients are curable with appropriate treatment 1

Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) - 5% of HL cases 1

• Characterized by lymphocyte-predominant "popcorn cells" rather than Reed-Sternberg cells
• Generally favorable prognosis, though management differs from CHL in some situations 1

Non-Hodgkin Lymphoma (NHL)

NHL represents a heterogeneous group requiring classification by aggressiveness and cell of origin:

B-Cell Lymphomas - 90% of NHL cases 2

Indolent B-Cell Lymphomas:

• Follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma
• Prognosis: Incurable but compatible with prolonged survival; quality of life must be balanced against treatment toxicity 2
• Key prognostic marker: Patients achieving event-free survival at 12 months (EFS12) experience mortality similar to the general population (SMR 1.19), while those failing to achieve EFS12 have significantly worse outcomes (SMR 3.14) 3

Aggressive B-Cell Lymphomas:

• Diffuse large B-cell lymphoma (DLBCL)
• Prognosis: More dangerous if untreated, but higher proliferation rates render them more chemosensitive; managed with curative intent 2

T-Cell Lymphomas - 10% of NHL cases 4

Peripheral T-Cell Lymphomas (PTCLs):

• PTCL not otherwise specified (PTCL-NOS): 26% of PTCLs, poor prognosis
• Angioimmunoblastic T-cell lymphoma (AITL): 18.5% of PTCLs, poor prognosis
• ALK-positive anaplastic large cell lymphoma (ALCL): 7% of PTCLs, favorable prognosis (though this decreases with older age and higher risk scores)
• ALK-negative ALCL: 6% of PTCLs, intermediate prognosis
• Enteropathy-associated T-cell lymphoma: <5% of PTCLs, poor prognosis

Critical distinction: PTCLs are less responsive to standard chemotherapy and carry poorer prognosis compared to DLBCLs, with the notable exception of ALK-positive ALCL 4

Prognostic Stratification

For Hodgkin Lymphoma

Risk stratification is based on staging with PET/CT and presence of risk factors 5:

• Early-stage favorable: Excellent prognosis with minimal treatment
• Early-stage unfavorable: Very good prognosis with combined modality therapy
• Advanced-stage: Good prognosis with intensive chemotherapy ± radiotherapy

For Non-Hodgkin Lymphoma

Multiple prognostic indices exist with varying utility 3:

• International Prognostic Index (IPI): c-statistics 0.593-0.612 for event-free survival
• Follicular Lymphoma International Prognostic Index (FLIPI): Demonstrates utility in predicting long-term outcomes
• MALT International Prognostic Index (MALT-IPI): c-statistics 0.683-0.714 for overall survival; recommended for risk stratification in marginal zone lymphomas 3

Critical Prognostic Markers by Subtype

Mycosis Fungoides (cutaneous T-cell lymphoma):

• T1 stage (<10% skin involvement): 100% 5-year survival
• T2 stage (>10% skin involvement): 67-96% 5-year survival
• T3 stage (tumor stage): 51-80% 5-year survival
• T4 stage (erythroderma): 41% 5-year survival 6

CD30+ Primary Cutaneous Large T-Cell Lymphomas:

• Excellent prognosis: 96-100% 5-year survival 6

CD30-negative Primary Cutaneous Large T-Cell Lymphomas:

• Aggressive behavior: 15-21% 5-year survival 6

Primary Cutaneous B-Cell Lymphomas:

• Follicle center-cell lymphomas (head/trunk): 94-97% 5-year survival
• Large B-cell lymphomas of the leg: 52% 5-year survival (poorer prognosis, especially in elderly) 6

Common Pitfalls

Do not assume all lymphomas are curable: While HL and aggressive NHL are treated with curative intent, indolent NHL remains incurable despite long survival, requiring a fundamentally different treatment philosophy 2.

Do not overlook histologic transformation at relapse: Repeat biopsy is essential in relapsed NHL to exclude transformation to more aggressive histology, which dramatically changes prognosis and management 7.

Do not apply DLBCL outcomes to PTCL: Standard CHOP chemotherapy yields disappointing results in most PTCLs (except ALK-positive ALCL), necessitating consideration of more intensive approaches or clinical trials 4.

Do not ignore the prognostic significance of early treatment failure: Patients with indolent NHL who fail to achieve EFS12 represent a high-risk subset requiring more aggressive management strategies 3.